{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T15:49:00Z","timestamp":1788709740235,"version":"build-2803163510"},"reference-count":22,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:00:00Z","timestamp":1697414400000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019914","name":"Flatiron Health","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100019914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,9,26]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Examine whether data from early access to medicines in the USA can be used to inform National Institute for Health and Care Excellence (NICE) health technology assessments (HTA) in oncology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Oncology-based community and academic treatment centres in the USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients present in a nationwide electronic health record (EHR)-derived deidentified database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Cancer drugs that underwent NICE technology appraisal (TA) between 2014 and 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The count and follow-up time of US patients, available in the EHR, who were exposed to cancer drugs of interest in the period between Food and Drug Administration (FDA) approval and dates relevant to the NICE appraisal process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 59 of 60 TAs analysed, the cancer therapy was approved in the USA before the final appraisal by NICE. The median time from FDA approval to the publication of NICE recommendations was 18.5 months, at which time the US EHR-derived database had, on average, 269 patients (SD=356) exposed to the new therapy, with a median of 75.3 person-years (IQR: 13.1\u2013173) in time-at-risk. A case study generated evidence on real-world overall survival and treatment duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Across different cancer therapies, there was substantial variability in US real-world data accumulated between FDA approval and NICE decision milestones. The applicability of these data to generate evidence for HTA decision-making should be assessed on a case-by-case basis depending on the intended HTA use case.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-074559","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:57:05Z","timestamp":1697543825000},"page":"e074559","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6474-029X","authenticated-orcid":false,"given":"Philani","family":"Mpofu","sequence":"first","affiliation":[{"name":"Flatiron Health Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seamus","family":"Kent","sequence":"additional","affiliation":[{"name":"Flatiron Health Inc, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1ll","family":"J\u00f3nsson","sequence":"additional","affiliation":[{"name":"Data and Analytics, National Institute for Health and Care Excellence, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlan","family":"Pittell","sequence":"additional","affiliation":[{"name":"Flatiron Health Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Groves","sequence":"additional","affiliation":[{"name":"Managed Access Team, National Institute for Health and Care Excellence, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy","family":"Altomare","sequence":"additional","affiliation":[{"name":"Flatiron Health Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Copeland","sequence":"additional","affiliation":[{"name":"Flatiron Health Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrujal","family":"Baxi","sequence":"additional","affiliation":[{"name":"Flatiron Health Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Bargo","sequence":"additional","affiliation":[{"name":"Flatiron Health Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Sujenthiran","sequence":"additional","affiliation":[{"name":"Flatiron Health Inc, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4251-2912","authenticated-orcid":false,"given":"Blythe","family":"Adamson","sequence":"additional","affiliation":[{"name":"Flatiron Health Inc, New York, New York, USA"},{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"2025121511092709000_13.10.e074559.1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462320000215"},{"key":"2025121511092709000_13.10.e074559.2","unstructured":"National Institute for Health and Care Excellence . NICE real-world evidence framework, Available: https:\/\/www.nice.org.uk\/corporate\/ecd9\/chapter\/overview [Accessed 25 Aug 2022]."},{"key":"2025121511092709000_13.10.e074559.3","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-018-3669-6"},{"key":"2025121511092709000_13.10.e074559.4","unstructured":"National Institute for Health and Care Excellence . Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy, . 2018 Available: https:\/\/www.nice.org.uk\/guidance\/ta520\/documents\/final-appraisal-determination-document"},{"key":"2025121511092709000_13.10.e074559.5","unstructured":"National Institute for Health and Care Excellence . Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer, . 2022 Available: https:\/\/www.nice.org.uk\/guidance\/ta781\/documents\/final-appraisal-determination-document-2"},{"key":"2025121511092709000_13.10.e074559.6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.16183","article-title":"Cancer therapy approval Timings, review speed, and publication of pivotal registration trials in the US and Europe, 2010-2019","volume":"5","author":"Lythgoe","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025121511092709000_13.10.e074559.7","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1111\/1475-6773.12872","article-title":"Development and validation of a high\u2010quality composite real\u2010world mortality endpoint","volume":"53","author":"Curtis","year":"2018","journal-title":"Health Serv Res"},{"key":"2025121511092709000_13.10.e074559.8","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/1475-6773.13669","article-title":"Validation analysis of a composite real\u2010world mortality endpoint for patients with cancer in the United States","volume":"56","author":"Zhang","year":"2021","journal-title":"Health Serv Res"},{"key":"2025121511092709000_13.10.e074559.9","doi-asserted-by":"crossref","unstructured":"Ma X , Long L , Moon S , et al . Comparison of population characteristics in real-world clinical oncology databases in the US: flatiron health, SEER, and NPCR. Oncology [Preprint] 2020. doi:10.1101\/2020.03.16.20037143","DOI":"10.1101\/2020.03.16.20037143"},{"key":"2025121511092709000_13.10.e074559.10","unstructured":"Birnbaum B , Nussbaum N , Seidl-Rathkopf K , et al . Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv:2001.09765 [Preprint] 2020."},{"key":"2025121511092709000_13.10.e074559.11","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"2025121511092709000_13.10.e074559.12","unstructured":"National Health Service . Cancer drugs fund, Available: https:\/\/www.england.nhs.uk\/cancer\/cdf [Accessed 18 Oct 2022]."},{"key":"2025121511092709000_13.10.e074559.13","unstructured":"National Institute for Health and Care Excellence . Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer, Available: https:\/\/www.nice.org.uk\/guidance\/TA531 [Accessed 25 Aug 2022]."},{"key":"2025121511092709000_13.10.e074559.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m4856","article-title":"START-RWE: structured template for planning and reporting on the implementation of real world evidence studies","volume":"372","author":"Wang","year":"2021","journal-title":"BMJ"},{"key":"2025121511092709000_13.10.e074559.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2025121511092709000_13.10.e074559.16","unstructured":"Keytruda product information (EMA . European Medicines Agency, Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf"},{"key":"2025121511092709000_13.10.e074559.17","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/pds.5091","article-title":"Real\u2010World effectiveness of pembrolizumab in previously treated non\u2010small cell lung cancer: a population\u2010based cohort study","volume":"29","author":"Murteira","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121511092709000_13.10.e074559.18","doi-asserted-by":"crossref","unstructured":"Descourt R , Greillier L , Perol M , et al . First-line pembrolizumab monotherapy for PD-L1-positive (TPS\u2265 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: a national french bispective multicentric cohort\u2014ESCKEYP trial (GFPC 05-2018). JCO 2021;39.(15_suppl) doi:10.1200\/JCO.2021.39.15_suppl.9091","DOI":"10.1200\/JCO.2021.39.15_suppl.9091"},{"key":"2025121511092709000_13.10.e074559.19","doi-asserted-by":"crossref","unstructured":"Agg H , Winfree KB , Zhu YE , et al . A real-world analysis of non-small cell lung cancer patients treated with pembrolizumab or pembrolizumab in combination with pemetrexed and platinum. JCO 2020;38.(5_suppl) doi:10.1200\/JCO.2020.38.5_suppl.53","DOI":"10.1200\/JCO.2020.38.5_suppl.53"},{"key":"2025121511092709000_13.10.e074559.20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.11113","article-title":"Association between first-line immune checkpoint inhibition and survival for medicare-insured patients with advanced non\u2013small cell lung cancer","volume":"4","author":"Kehl","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025121511092709000_13.10.e074559.21","doi-asserted-by":"crossref","unstructured":"Velcheti V , Chandwani S , Chen X , et al . First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: a real-world analysis of time on treatment in US community oncology practices. Annals of Oncology 2018;29. doi:10.1093\/annonc\/mdy486.002","DOI":"10.1093\/annonc\/mdy486.002"},{"key":"2025121511092709000_13.10.e074559.22","unstructured":"Friis RH , Sellers T . Epidemiology for public health practice. Jones & Bartlett Learning, 2020."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-074559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:09:35Z","timestamp":1765825775000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-074559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,17]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/bmjopen-2023-074559"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-074559","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}